Vimizim Elosulfase Alpha Application Scope

Vimizim (elosulfase alfa) is an enzyme replacement therapy indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

Vimizim Elosulfase Alpha Characteristics

Ingredients: Elosulfase alfa is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme.
Properties: Elosulfase alfa is a soluble dimeric protein, with each monomer containing 496 amino acids and an approximate molecular mass of 55 kDa for the peptide chain.
Specification: Vimizim is supplied as a concentrated solution for intravenous infusion, with each vial containing 5 mg/5 mL (1 mg/mL) of elosulfase alfa.

Packaging Specification:

Ingredients: Each vial contains 5 mg of elosulfase alfa in 5 mL of solution.
Properties: The solution is clear to slightly opalescent and colorless to pale yellow.
Specification: Single-use vials containing 5 mg/5 mL (1 mg/mL) of elosulfase alfa.
Storage: Store vials at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Protect from light.
Effective period: Refer to the expiration date on the vial for shelf life information.
Approval Number: Refer to the local regulatory authority for the specific approval number.
Manufacturer: BioMarin Pharmaceutical Inc.

Guidelines For The Use Of Vimizim Elosulfase Alpha

Dosage and Administration: The recommended dose is 2 mg per kg of body weight administered once a week as an intravenous infusion over a minimum of 3.5 to 4.5 hours, based on infusion volume. Pre-treatment with antihistamines with or without antipyretics is recommended 30 to 60 minutes prior to the start of the infusion.
Adverse Reactions: Common adverse reactions include pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue. Serious hypersensitivity reactions, including anaphylaxis, have been reported.

Medication Limitations

Contraindications: There are no known contraindications for Vimizim.
Precautions: Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions and require additional monitoring. Appropriate medical support should be readily available during Vimizim administration.

Vimizim Elosulfase Alpha Interactions

Drug Interactions: No formal drug interaction studies have been conducted with Vimizim.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.